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IntroductIon
Oral anticoagulant therapy is essential for 
the treatment and prevention of many throm-
boembolic disorders [1-3]. In atrial fibrillation, 
long term anticoagulation treatment can reduce 
the annual risk of stroke by two thirds [4,5]. 
Such treatment compares favourably with the 
alternative, aspirin treatment [6]. However, the 
pharmacokinetic profile of vitamin K antago-
nists (VKAs) is complex [7], and monitoring is 
required to avoid both thromboembolic events 
associated with low intensity anticoagulation 
and haemorrhagic complications associated 
with higher intensity. Target levels of oral anti-
coagulation are disease specific and measured 
with the international normalised ratio (INR). 
However, in most of therapeutic indications, the 
recommended range is 2.0-3.0 [8]. To attain INR 
values within this range, patients are routinely 
monitored and their VKA doses are adjusted 
when necessary. It is well known that long term 
stability is difficult to achieve because of unex-
pected fluctuations of the INR values in patients, 
which can be attributed to numerous factors in-
cluding change in diet, poor adherence to treat-
ment, alcohol consumption, seasonal variations, 
and drug to drug interactions [9,10]. 
The aim of this study is to evaluate the level 
of anticoagulation control in patients treated 
with VKA for various indications in a clinical 
practice setting and to explore the relationship 
between anticoagulation control and adherence 
to VKA treatment.
PatIents and methods
Sources of data
The data we used were retrieved from three 
different administrative databases of three Lo-
cal Health Units (LHU) located in the centre 
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aBstract
Oral anticoagulant therapy is essential for the treatment and prevention of many thromboembolic disorders. 
The aim of the present study is to evaluate the level of anticoagulation intensity in patients treated with vita-
min K antagonists (VKAs) in a clinical practice setting and to explore the relationship between anticoagulation 
intensity and adherence to VKA treatment. We conducted a retrospective cohort study using the administrative 
databases of three Italian Local Health Units. Patients were enrolled if they had filled at least one prescription 
for VKAs (ATC code B01AA) between January 1st, 2007 and June 30th, 2008. In the same period all determi-
nations of the international normalised ratio (INR) were collected. The parameters evaluated were anticoagula-
tion control and adherence to VKA treatment.
The survey showed that only 47.9% and 56.3% of INR determinations, in VKA naïve and established patients 
respectively, were into the recommended range (2.0-3.0). Moreover, the percentage of INR determination below 
the recommended range was higher than the percentage of INR determination above the recommended range 
for both naïve and established patients. Moreover, adherence to VKA treatment was poor both in naïve and 
established patients and, consequently, anticoagulation control is poor. Also in patients with the highest adher-
ence to VKA treatment, only about 60% of INR determinations were into the recommended range. Our findings 
evidence that the anticoagulation control in clinical practice settings is still unsatisfactory and it is necessary to 
evaluate interventions to increase the amount of time at which patients’ INR are within the recommended range.
Keywords: adherence to treatment, anticoagulation control, INR, vitamin K antagonists, administrative data-
bases
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these drugs during the enrolment period. Naïve/
established patients were classified according to 
the absence/presence of prescriptions for VKAs 
filled during the year preceding the enrolment 
date. Patients who were transferred to another 
LHU or died or had no INR determinations 
during the year following the enrolment date 
were excluded.
Adherence to treatment
Adherence to treatment was calculated as 
the sum of “adequately dosed” days for VKAs 
divided by the duration in days of the follow up 
period (365) multiplied by 100. Tablets in each 
prescription were divided by the elapsed time in 
days up to the following prescription. If the aver-
age number of tablets per day was in the range 
0.5-2.0, the number of days up to the follow-
ing prescription was classified as “adequately 
dosed” for VKAs. Tablets prescribed into the last 
prescription contributed only for those account-
able until the end the follow up period.
Anticoagulation control
Anticoagulation control was calculated as 
the sum of INR determinations in the range 
2.0-3.0 divided by the overall number of INR 
determinations multiplied by 100. In order to 
avoid potential confounding effects of low or 
high number of INR determinations, the rela-
tionship between anticoagulation control and 
adherence to treatment was studied also in 
patients within 25 and 75 percentile of INR 
determinations.
and north of Italy and including approximately 
774,000 beneficiaries: “Health-assisted sub-
jects’ Database”, containing patients’ demo-
graphic data; “Medications Prescription Data-
base”, providing information for each medica-
tion prescription such as the prescribing phy-
sician’s number, the Anatomical-Therapeutic-
Chemical (ATC) code of the drug purchased, 
the number of packs, the number of units per 
pack, the dosages, the unit cost per pack and the 
prescription date; and “Laboratory test values 
database”, which includes the date of adminis-
tration for laboratory test, the type of laboratory 
test and description, and the laboratory test re-
sult. The patient code in each database permitted 
electronic linking among all three databases. In 
order to guarantee patient privacy, each subject 
was assigned an anonymous univocal numeric 
code. The researchers weren’t provided with 
identifiers related to patients. The local Eth-
ics Committee of each participating LHUs ap-
proved this study.
Cohort definition
This was a retrospective cohort study, which 
included all relevant medication prescription 
and laboratory test data over the study period 
for both naïve and established VKA users. Pa-
tients were enrolled if they had filled at least 
one prescription for VKAs (ATC code B01AA) 
between January 1st, 2007 and June 30th, 2008 
(enrolment period). The enrolment date of a 
given study subject was defined as the first date 
on which a patient filled a prescription for one of 
Heparins 
Antiplatelet 
agents 
Other 
antithrombotic 
agents 
Number of 
patients (%) 
INR determination 
(median, percentile 
25-percentile 75) 
VKA-naïve 
patients 
1,923 (62.5) 19 (10-29) 
• 11 (0.4) 26 (18-33) 
• 620 (20.2) 14 (6-23) 
• • 3 (0.1) 6 (5-12) 
• 382 (12.4) 19 (11-29) 
• • 136 (4.4) 15 (7-22) 
Total 3,075 (100.0) 18 (8-28)
VKA-
established 
patients
6,442 (83.0) 16 (12-25) 
• 7 (0.1) 20 (11-44) 
• 628 (8.1) 15 (7-24) 
• • 3 (0.1) 28 (1-31) 
• 587 (7.6) 16 (10-25) 
• • 2 (0.1) 24.5 (14-35) 
• • 89 (1.1) 11 (6-18.5) 
• • • 0 (0.0) …
Total 7,758 (100.0) 16 (12-25)
Table I
Concurrent 
antithrombotic drugs 
and number of INR 
determinations in 10,883 
VKAs treated patients
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established. Naïve patients were younger than 
established ones (73.5 ± 12.0 versus 75.8 ± 9.9) 
and prevalently male (51.0%). Concurrent anti-
thrombotic drugs and frequency of INR deter-
minations are presented in Table I. 
Most patients showed no concurrent anti-
thrombotic drug combined with VKAs both 
in naïve (62.5%) and in established patients 
(59.5%). Concurrent use of heparins or an-
tiplatelet agents resulted, respectively, in 12.4% 
and 20.2% of naïve patients and in 7.6% and 
8.1% of established patients (Table I). The 
median number of INR determination was 17 
(11-26) in the overall included cohort, ranging 
from 18 (8-28) in naïve patients to 16 (12-25) 
in established patients (Table I). On average, in 
the year of follow up 47.9% and 56.3% of INR 
determinations in naïve and established patients, 
respectively, resulted within the recommended 
range (2.0-3.0) (Table II).
Mean percentage of INR determination be-
low the recommended range was higher than 
mean percentage of INR determination above 
the recommended range for both naïve and es-
tablished patients (Table II).
Statistical analysis
Data were summarised as mean ± standard 
deviation (SD) or median (25-75 percentile) for 
continuous variable and as numbers (percent-
ages) of subjects for categorical variables. Pear-
son’s chi-square and one-way ANOVA tests were 
used to evaluate differences in baseline charac-
teristics across adherence levels. Multivariable 
median regression was used to estimate beta co-
efficient (β) and 95% confidence intervals (CIs) 
of achieving anticoagulation control as a function 
of adherence categories. To adjust for potential 
confounders, in the multivariable model we in-
cluded age, gender, and presence of thrombolytic 
drugs (yes/no) – at least two prescriptions in the 
follow up period of heparin (ATC code B01AB), 
antiplatelet agents (ATC code B01AC), and 
concurrent antithrombotic therapy (ATC code 
B01AD – enzymes, ATC code B01AE – direct 
thrombin inhibitors, ATC code B01AX – other 
antithrombotic agents). Two-tailed p-values less 
than 0.05 were considered statistically signifi-
cant. All analyses were conducted using SPSS 
for Windows, version 15.0.
results
A total of 16,339 patients were enrolled in 
the study. Of whom, 5,506 patients (33.7% of 
enrolled subjects) were excluded: 82 (0.5%) 
because they were transferred to another LHU, 
1,421 (8.7%) because they died and 4,003 
(24.5%) because they had not INR determi-
nations during the follow up period. A total 
of 10,833 patients were included in the study, 
5,531 men (51.0%) and 5,302 women (49.0%), 
with a mean age of 75.1 ± 10.6 (range 18-101) 
years. Most of the patients were aged 70-89 
years old (67.6% of men and 75.9% of wom-
en). Among included patients, 3,075 (28.4%) 
were classified as naïve and 7,758 (71.6%) as 
INR 
Mean  
(%)
Median 
(%)
Percentile 
25-percentile 75 (%)
VKA-naïve 
patients
< 2.0 35.4 28.8 15.4-47.9
2.0-3.0 47.9 50.0 33.3-66.7
> 3.0 16.7 13.3 0.0-25.0
VKA- 
established 
patients
< 2.0 25.7 20.0 7.7-36.4
2.0-3.0 56.3 58.3 42.5-73.1
> 3.0 18.0 14.3 4.0- 26.7
Table II
Percentages of INR determinations by range in naïve and established VKAs 
treated patients
Adherence 
(%) 
VKA-naïve VKA-established 
Nr. of patients (%) In-range INR (%) Nr. of patients (%) In-range INR (%) 
0-9 830 (27.0) 34.3 1,014 (13.1) 47.6 
10-19 289 (9.4) 49.0 616 (7.9) 52.4 
20-29 271 (8.8) 49.6 699 (9.0) 54.1 
30-39 218 (7.1) 50.0 539 (6.9) 55.9 
40-49 225 (7.3) 52.9 606 (7.8) 55.6 
50-59 243 (7.9) 51.0 801 (10.3) 58.4 
60-69 197 (6.4) 55.5 698 (9.0) 58.7 
70-79 175 (5.7) 53.4 487 (6.3) 58.7 
80-89 152 (4.9) 55.7 500 (6.4) 60.4 
> 90 475 (15.4) 57.8 1,798 (23.2) 60.0 
Total 3,075 (100.0) 47.9 7,758 (100.0) 56.3
Table III
INR control and VKA 
treatment adherence in 
naïve and established 
VKAs treated patients
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When only patients with a number of INR 
determinations within 25 and 75 percentile 
were studied (Table IV), mean percentage of 
INR determinations within the recommended 
range (2.0-3.0) varied from 46.2% in naïve pa-
tients with lowest adherence (0-9%) to 59.5% 
in those with highest adherence (> 90%) and 
from 53.1% in established patients with lowest 
adherence (0-9%) to 62.4% in those with high-
est adherence (> 90%). Results are presented 
in Figure 2. Overall, 55,6% of the patients in 
analysis had less than 60% of INR determina-
tions within the recommended range (2.0-3.0) 
during the year of follow up.
The multivariable median regression showed 
that anticoagulation control was related to adher-
ence with VKA treatment (+0.14% of the percent-
age of INR in range 2-3 for an increment of 1% 
of VKA treatment coverage, p < 0.001), use of 
heparins (-10.70%, p < 0.001), antiplatelet agents 
(-6.14%, p < 0.001), or concurrent antithrombotic 
therapy (-15.81%, p < 0.001), and to number of 
INR determinations (+0.06% of the percentage of 
Adherence to VKA treatment was poor both 
in naïve and established patients but higher in 
established patients (53.7 ± 33.5% versus 41.6 ± 
35.0%). According to the distribution by levels 
of adherence (Table III), highest frequency of 
patients was displayed by the lowest category 
of adherence in naïve patients (27.0%) and by 
the highest category of adherence in established 
patients (23.2%).
Both naïve and established patients seemed 
to be homogenously distributed into different 
levels of adherence. Similar results were ob-
tained when only patients with a number of INR 
determinations within 25 and 75 percentile were 
studied (Table IV).
Mean percentage of INR determinations 
within the recommended range (2.0-3.0) varied 
from 34.3% in naïve patients with lowest adher-
ence (0-9%) to 57.8% in those with highest ad-
herence (> 90%) and from 47.6% in established 
patients with lowest adherence (0-9%) to 60.0% 
in those with highest adherence (> 90%) (Table 
III). Results are presented in Figure 1.
Adherence 
(%) 
VKA-naïve VKA-established 
Nr. of patients (%) In-range INR (%) Nr. of patients (%) In-range INR (%) 
0-9 255 (19.2) 46.2 465 (10.2) 53.1 
10-19 129 (9.7) 48.8 307 (6.7) 54.9 
20-29 132 (9.9) 52.0 406 (8.9) 57.5 
30-39 105 (7.9) 52.8 310 (6.8) 58.5 
40-49 112 (8.4) 55.0 381 (8.4) 57.8 
50-59 110 (8.3) 54.2 487 (10.7) 60.8 
60-69 93 (7.0) 56.3 451 (9.9) 60.3 
70-79 78 (5.9) 56.4 294 (6.4) 61.9 
80-89 73 (5.5) 54.5 322 (7.1) 62.1 
> 90 244 (18.3) 59.5 1,139 (25.0) 62.4 
Total 1,331 (100.0) 53.1 4,562 (100.0) 59.4
Table IV
INR control and VKA 
treatment adherence in 
naïve and established 
VKAs treated patients 
(developed only on 
patients with a number 
of INR determinations 
between 25 and 75 
percentile)
Figure 1
INR control and VKA 
treatment adherence in 
naïve and established 
VKAs treated patients
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anticoagulation control is poor. Also in patients 
with the highest adherence to VKA treatment, 
only about 60% of INR determinations were 
into the recommended range. It is possible that 
we have overestimated the non adherence to 
treatment since in clinical situations like deep 
venous thromboembolism as well as pulmo-
nary embolism the length of VKA treatment 
was time-limited (weeks or months) and not 
chronically used. On the other hand, for the most 
common indications for anticoagulation, max-
imising the length of time at which a patient’s 
international normalised ratio is in the therapeu-
tic range of 2-3 should minimise the risk of both 
haemorrhagic and thromboembolic events [8]. 
In our work, factors positively related to antico-
agulation control were adherence to treatment 
and frequency of INR determination, while a 
concurrent prescription of other antithrombotic 
drugs was negatively related to anticoagulation 
control. Our results seem to be in agreement 
with previous reports that evidenced the role 
of various factors, such as co-medications or 
chronic care management, on the intensity of 
anticoagulation control as well as patients out-
comes [14,15]. Ensuring adequate monitoring of 
patients on oral anticoagulants and to maintain 
the intensity of anticoagulation within a safe 
INR in range 2-3 for a one unit increment of INR 
determinations, p = 0.001) (Table V).
dIscussIon
This study, in our knowledge the first in 
Italy to provide an evaluation about the degree 
of anticoagulation control in a large cohort of 
VKA treated patients as well as to explore the 
relationship between adherence to VKA treat-
ment and anticoagulation control, showed that 
only 47.9% and 56.3% of INR determinations, 
in naïve and established patients respectively, 
were into the recommended range. Moreover, 
the percentage of INR determination below 
the recommended range was higher than the 
percentage of INR determination above the 
recommended range for both naïve and estab-
lished patients. Other studies, performed in a 
clinical practice settings, have shown that pa-
tients were prone to spend more time with ratio 
below than above the therapeutic range [11,12]. 
These findings could be attributed to the effects 
of low dose of VKA treatment as a consequence 
of an overestimate risk of haemorrhage: physi-
cians estimate the rate of intracranial bleeding 
related to the use of warfarin ten times higher 
than the rate reported in the literature [13]. A 
recent systematic review [8] found a strong as-
sociation between anticoagulation intensity and 
outcomes: the risk of haemorrhage significantly 
increased when the INR exceeded 3, while the 
risk of thromboembolism was greatest when 
the INR was below 2. When both haemorrhagic 
and thromboembolic events are considered, the 
data show that patients were safer with a ratio 
slightly above, rather than below, the therapeu-
tic range of 2-3 [8]. Physicians should be aware 
of this finding and should adjust their clinical 
practices accordingly, by aggressively correct-
ing subtherapeutic ratios and avoiding overreac-
tion to ratios that narrowly exceed 3.
Adherence to VKA treatment, the second 
aspect that we analysed, was poor both in naïve 
and established patients and, consequently, the 
Figure 2
INR control and VKA 
treatment adherence in 
naïve and established 
VKAs treated patients 
(developed only on 
patients with a number 
of INR determinations 
between 25 and 75 
percentile)
β 95% CI p 
VKA treatment coverage (%) 0.14 0.13 0.15 0.000 
Gender (male) 0.30 -0.54 1.14 0.487 
Age (years) 0.02 -0.02 0.06 0.223 
Heparins -10.70 -12.03 -9.37 0.000 
Antiplatelet agents -6.14 -7.38 -4.90 0.000 
Other antithrombotic drugs -15.81 -24.13 -7.48 0.000 
Nr. of INR determinations 0.06 0.02 0.09 0.001
Table V
Multivariable median regression on INR control in VKAs treated patients
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and effective range is a crucial point for chronic 
care management to avoid an important cause 
of morbidity and mortality and a significant 
burden on health-care resources [16]: previous 
systematic reviews have shown that 4.9-7.7% of 
hospital admissions are related to adverse drug 
events and a median of 4.3% of admissions are 
considered preventable [17-19]. 
Findings of the present study must be inter-
preted in the light of some limitations. Reason 
for prescribing VKA treatment was not avail-
able, thus, as we have previously discussed, 
the evaluation of the appropriateness regarding 
the length of treatment is uncertain. Moreover, 
only records of INR determination reimbursed 
by the National Health Service were available. 
However, we believe that both these situations 
regard a minority of subjects. 
In conclusion, the present study was based 
on participants recruited from the general popu-
lation through the analysis of some databases 
of the National Health System. The link among 
the so-called administrative databases is simple 
to perform and does not require a specific epi-
demiological organisation, thus the cost is very 
low. We believe that a continuous monitoring 
of both VKA therapy and anticoagulation in-
tensity in a practice clinical setting, as we have 
proposed, could contribute to improve the ap-
propriateness of VKA treatment as well as the 
patient outcomes.
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